Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar

Merck (MRK) shares gain, Citi upgrades to buy as estimates ahead of consensus

April 13, 2023 10:31 AM EDT

Merck (NYSE: MRK) was lifted to Buy from Neutral, with its price target raised to $130 from $105 by Citi analyst Andrew Baum on Thursday.

The analyst said the firm's new estimates are 2-25% ahead of consensus, while their NPV "assumes a very conservative Keytruda... More